bg-img9.jpg
8.jpg
Cell Therapy Manufacturing & Gene Therapy Congress

We are pleased to announce our participation as a sponsor at the upcoming Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam. The event will focus on connecting cell and gene therapy leads to drive manufacturing and commercialization through direct access to innovative discovery, product development and regulatory know-how. We are honored to showcase our global integrated solution for cell therapy clinical and commercial development in conjunction with our parent company, Thermo Fisher Scientific.

Topic: Cell Therapy Solutions, Content: Blog

Decentralized Manufacture: The Drivers and Barriers

The emergence of advanced therapeutics, including cell and gene-based therapies (CGTs), presents significant opportunities for treating unmet clinical needs, and specifically, has demonstrated the potential to provide personalized therapies. Amidst the exciting science and clinical opportunities however, there are unique challenges that arise from manufacturing and delivering patient-specific CGTs.

Topic: Cell Therapy Solutions, Content: Blog

Expanding our Global Footprint: Supporting Cell and Gene Therapy in Japan

As I mentioned in my previous blog, favorable regulations in Japan are impacting cell therapy clinical trials conducted by the biopharmaceutical industry on a global scale.  To meet this increasing demand Fisher BioServices has expanded our cryogenic service capabilities in Tokyo, Japan.  This expansion enables our customers to seamlessly conduct clinical trials across multiple geographies and provide patients around the world with access to life changing therapies. 

Topic: Cell Therapy Solutions, Content: Blog

Cell Therapy Clinical Trials and the Mad Dash to Japan

When Shinzo Abe was re-elected as Japan's Prime Minister he aggressively embarked on a challenge to revive Japan's struggling economy. With the introduction of Abenomics, an economic policy that includes "three arrows" of fiscal stimulus, monetary easing, and structural reforms, the ball was set in motion to redefine Japan's standings within the global market.

Topic: Cell Therapy Solutions, Content: Blog

CAR T-Cell Therapy: High Risk, High Reward Part 2

As discussed in Part 1 of this blog series, Chimeric Antigen Receptor (CAR) T-cells are having an incredible impact on the cell therapy industry.  However, despite the many success stories, there are also several items that require consideration if we are to truly harness the potential of this type of therapy.  Let’s begin by exploring some of the unresolved questions and issues surrounding CAR T-cell therapy.

Topic: Cell Therapy Solutions, Content: Blog

CAR T-Cell Therapy: High Risk, High Reward Part 1

Of all the advances in medicine recently, cellular therapy is perhaps the most intriguing. It is a fast-paced, ever changing market that tests the boundaries of innovation and has forever changed the way we approach certain diseases. However, this type of medical discovery comes with its fair share of risk, but when all goes according to plan, the rewards can be great.

Topic: Cell Therapy Solutions, Content: Blog

Shooting for the Moon: A New Cancer Immunotherapy Initiative

In 1962, President John F. Kennedy electrified the nation when he declared our intent to send a man to the moon. This year, President Obama declared a new “shoot for the moon” endeavor: to find an effective immunotherapy treatment for cancer by the year 2020.

Topic: Cell Therapy Solutions, Content: Blog

Expansion Cohort Clinical Trials and Your Cryogenic Supply Chain

One advantage to the traditional phase 1, 2, and 3 format of clinical trials is that it allows reasonable forecasting with regard to the clinical supply chain. This phase 1-2-3 format is rapidly changing, however, especially with regard to biological therapies, as more and more clinical trials include expansion cohorts. If you are planning clinical trials for a cell-based therapy that must be maintained in liquid nitrogen, and may potentially take the expansion cohort route, you should consider the impact on your distribution capabilities as soon as possible.

Topic: Cold-Chain Logistics, Topic: Cell Therapy S..........

Gut Bacteria Rivals Immunotherapies in Cancer Treatment

The human gut contains more than 100 trillion bacteria from perhaps 500 or more different species. In fact, gut bacteria outnumber the cells in the human body. The vast number of these bacteria has caused researchers to take a closer look at how they are related to health and disease. Now, breaking scientific research suggests that gut bacteria may be more important than anyone previously realized: they appear to be effective cancer treatments.

Topic: Laboratory Processing, Topic: Cell Therapy ..........

The Link Between Epigenetics and CRISPR-Cas9

When it was first released in 2012, the CRISPR-Cas system stunned scientists with its potential for revolutionizing biological research. Researchers initially noticed that bacterial genomes often contain “clustered regularly interspaced short palindromic repeats,” now dubbed CRISPR sequences. When scientists provide the Cas enzyme with a guide RNA sequence, they can tell it precisely where to slice the DNA. This allows unprecedented control over DNA slicing and insertion of new genetic code.

Topic: Laboratory Processing, Topic: Cell Therapy ..........

Increasing Global Cell Therapy Awareness: ISCT 2016

We are pleased to announce our participation as a platinum sponsor at next week's International Society for Cellular Therapy (ISCT) 22nd Annual Meeting in Singapore. This will be the first time that the ISCT Annual Meeting will be held in Asia and is a reflection of the increasing global awareness of the importance of Asia in the field of Cellular Therapies. With over 1000 international delegates registered to attend, ISCT 2016 is a great opportunity to network with experts within the global cell therapy arena. We are honored to showcase our global integrated solution for cell therapy clinical and commercial development in conjunction with our parent company, Thermo Fisher Scientific.

Topic: Cell Therapy Solutions, Content: Blog

Amazing Samples: Buccal Up for Some Cheeky Research

Most researchers know about buccal cells  the easily sloughed-off cells from the inside of the cheek. The collection of these cells is relatively non-invasive, which gives it many of the same advantages as spit and mucus that we’ve already discussed. Because of this, many studies, including some in social science, utilize buccal swabs to increase the amount of data they’re collecting.

However, even if it’s popular, don’t let that diminish its value. From biomarker studies to stem cell research, buccal cells have proven time and time again to be a hugely useful source of biological data. Last time in our Amazing Samples blog series, we scratched the surface of research with skin cells. This time, buccal up and get ready for a cheekier kind of Amazing Sample!

Topic: Biobanking and Biorepository, Topic: Cell T..........